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Abstract
Rational Eszopiclone and zolpidem are hypnotics that
differentially affect sleep and waking states in adult
animals. Therefore, it was of interest to compare their
effects on the states of sleep and wakefulness in aged
animals.
Objectives Our objective was to determine the responses to
eszopiclone and zolpidem vis-à-vis sleep and waking states
in aged guinea pigs and to compare them with the effects of
these hypnotics in adult animals.
Methods Aged guinea pigs were prepared to monitor sleep
and waking states and to perform a frequency analysis of
the EEG. Eszopiclone and zolpidem were administered
intraperitoneally (1, 3, and 10 mg/kg).
Results Eszopiclone produced a more rapid and greater
increase in NREM sleep as well as longer duration episodes
of NREM sleep compared with zolpidem. There was also a
significant increase in the latency to REM sleep with
eszopiclone, but not with zolpidem. EEG power during
NREM sleep increased in the delta band and decreased in
the theta band following eszopiclone administration,
whereas zolpidem had no effect on any of the frequency
bands analyzed.
Conclusions Inagedaswellasadult guineapigs,eszopiclone
is a more effective hypnotic insofar as it produces a shorter
latency to NREM sleep, a greater amount of NREM sleep and
EEG delta waves. Differences in the effects produced by
eszopiclone and zolpidem as a function of the aging process
likely reflect the fact that they bind to different subunits of the
GABAA receptors, which are differentially reactive to the
aging process.
Keywords Hypnotics.NREMsleep.EEGpower.Aging
Introduction
In humans, old age is characterized by a decrease in
nonrapid eye movement (NREM) and REM sleep as well as
an increase in sleep latency and in the number of
awakenings (Bliwise 2005). Sleep-related disorders, such
as insomnia, sleep apnea, and periodic limb movements,
occur more frequently in elderly individuals than in adults
(Ancoli-Israel et al. 1985; Foley et al. 1995). There is also
an increase in sleep disorders in the aged that is reflected by
the enhanced use of hypnotics (Mendelson 1987). In
addition, the aging brain appears to be more sensitive to
the sedative effects of classic hypnotics, such as benzo-
diazepines and cognitive dysfunctions, which are more
prevalent in the elderly, may be aggravated by their use
(Hemmeter et al. 2000). In the elderly, the long plasma
elimination half lives of the benzodiazepines and their
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oxidative hydroxylation (Lader 1993). Because aged
individuals are less able to compensate for impairments
caused by these hypnotics, the use of benzodiazepines to
treat insomnia, especially in the elderly, has been consid-
ered problematic (Hemmeter et al. 2000). However, unlike
classic hypnotics, nonbenzodiazepine hypnotics, such as
zopiclone (a cyclopyrrolone derivative) whose s-isomer is
eszopiclone and zolpidem (an imidazopyridine derivative)
have fewer adverse effects (Declerck et al. 1992; Hemmeter
et al. 2000; Lader 1992; Lancel 1999; Morin 2006; Noble et
al. 1998).
Zopiclone and zolpidem act by potentiating the
benzodiazepine-GABAA receptor complex by binding to
different GABAA receptor subunits. Thus, zopiclone (or
eszopiclone) exhibits considerable activity at GABAA
receptors containing α1, α2, α3, and α5 subunits (Damgen
and Luddens 1999; Davies et al. 2000; Smith et al. 2001).
On the other hand, zolpidem displays a very high and
selective affinity for α1 subunits with significantly less or
no affinity for α2, α3, and α5 subunits (Sanna et al. 2002).
Certain of the subunits of GABAA receptors that are
activated by the preceding hypnotics display age-related
changes in activity (Rissman et al. 2007). Therefore, it was
of interest to compare the hypnotic actions of eszopiclone
and zolpidem in old age. In addition, data from these
studies would establish a foundation for understanding the
cellular bases that are responsible for changes in sleep
patterns as well as the effectiveness of hypnotics in the
elderly, which at present are unknown.
We recently examined the hypnotic effects of eszopi-
clone and zolpidem in the adult guinea pig (Xi and Chase
2008). We found that eszopiclone, compared with zolpidem,
has a pharmacological profile in the adult guinea pig (4–
7 months old) that is characterized by a more rapid onset of
hypnotic action and an increased amount of time spent in
NREMsleep.Inaddition,eszopicloneproducedanincreasein
EEG delta power, whereas zolpidem had no effect on delta
activity. While our previous study and a number of other
reports have described the hypnotic effects of eszopiclone (or
zopiclone) and zolpidem in adult animals (Chen et al. 2005;
Depoortere et al. 1991;G a u t h i e re ta l .1997;G o t t e s m a n n
et al. 1998; Mailliet et al. 2001; Noguchi et al. 2004;
Stutzmann et al. 1992; Xi and Chase 2008), there have been
no quantitative studies that have directly compared the
effects of eszopiclone and zolpidem on the states of sleep
and wakefulness in aged animals or related these effects to
those produced in adult animals. Therefore, in the present
study, we examined the effects of the intraperitoneal
injection of eszopiclone and zolpidem on sleep and waking
states, as well as on EEG power, in chronically instrumented,
unanesthetized aged guinea pigs. We also compared these
data with the effects produced by eszopiclone and zolpidem
in adult animals.
Materials and methods
Animals and surgical procedures
Experiments were performed on five Hartley guinea pigs
(three females and two males; age 28±2 months, body
weight 1.10±0.06 kg) obtained from and determined to be
in good health by the VA Greater Los Angeles Healthcare
System (VAGLAHS). A variety of systems in the guinea
pig, and specifically the central nervous system, exhibit
age-related changes in animals that are 24 to 36 months
old (Abalo et al. 2005; Gabella 2001; Hiller et al. 1992;
McDougall and Schuelert 2007; Nozawa et al. 1997; Zhang
et al. 2005). Therefore, the guinea pigs that were used in the
present study were classified as “aged”. Animals, which
were housed in a temperature (22±1°C) and humidity (50–
70%) controlled environment with a 12:12-h light/dark
cycle (lights on from 600–1800 hours), had ad libitum
access to food and water.
The following procedures were carried out in order to
monitor the behavioral states of sleep and wakefulness and
to determine the effects of intraperitoneally administered
eszopiclone and zolpidem. Briefly, under ketamine/xylazine
(45/5 mg/kg, im) anesthesia, using sterile surgical procedures,
each guinea pig was implanted with electrodes for recording
the cortical electroencephalogram (EEG), the electrooculo-
gram(EOG),andtheelectromyogram(EMG).TorecordEEG
activity, screw electrodes were implanted bilaterally in the
calvarium overlying the cortex at the following coordinators
(relative to bregma): 2 mm anterior, 2 mm lateral; 5 mm
posterior, and 3 mm lateral. EMG electrodes were inserted
bilaterally into the dorsal neck muscles. A Winchester plug,
connected to these electrodes, was bonded to the calvarium
with acrylic cement. Following surgery, antibiotics were
administrated both systemically and topically. After recovery
from surgery, each guinea pig was adapted to the recording
environment on a daily basis for at least 2 weeks.
Procedures were conducted in accordance with the Guide
for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Academic Press,
WashingtonDC,1996)andapprovedbythe AnimalResearch
Committee of the VAGLAHS, and all efforts were made to
minimize the number of animals used in this study.
Drug administration
Experimental sessions were conducted between 1100 and
1600 hours. Eszopiclone (Sepracor Canada Ltd; Windsor,
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NJ) were separately administered, intraperitoneally, at doses
of 1, 3, and 10 mg/kg (0.5 ml). The doses of eszopiclone
and zolpidem that were used in the present study are within
the range of those typically employed when these sub-
stances are administered as hypnotics in experimental
animals (Chen et al. 2005; Depoortere et al. 1991; Gauthier
et al. 1997; Gottesmann et al. 1998; Mailliet et al. 2001;
Noguchi et al. 2002, 2004; Stutzmann et al. 1992; Xi and
Chase 2008). Vehicle was injected as a control (50 mM
acetate buffer solution, pH 4.5, 0.5 ml). Each animal
received injections of doses of 1, 3, and 10 mg/kg of both
drugs and vehicle in a randomized protocol, which were
administrated during the first 10 min of each experimental
session. At least 2 days (>2 days) transpired between each
injection session in order to make sure that all drug effects
were reversible and did not impact responses produced by
subsequent drug injections.
Recording and data analysis
The behavioral states of wakefulness, NREM sleep, and
REM sleep were scored on the basis of polygraphic records
which included EEG, EOG, and EMG data that were
monitored and digitized using a Macintosh computer
running AxoGraph X software (AxoGraph Scientific,
Sydney, Australia); polygraphic data were scored in 30-s
epochs according to previously described criteria (Escudero
and Vidal 1996; Ibuka 1984; Tobler and Franken 1993).
The following dependent variables were determined for
each recording session: (1) percentage of time spent in
wakefulness, NREM, and REM sleep; (2) latency to the
onset of the first episode of NREM and REM sleep;
because injections were carried out during wakefulness,
there was no measure of the latency to wakefulness; (3)
number of episodes of each behavioral state per hour
(frequency); and (4) duration of episodes of each behavioral
state. EEG power during each state was determined on the
basis of a fast Fourier transform analysis of the EEG.
Successive 15-s time segments of EEG signals in 1 Hz bins
from 0.5–30 Hz over a period of 2 h were analyzed using
AxoGraph X software. The relative power (percent of total)
in each of the following frequency bands during each state
was determined: delta (0.5–4 Hz); theta (4–9 Hz); sigma
(9–14 Hz); and beta (14–30 Hz). Experimental data are
expressed as means ± SEM. The statistical significance
of the difference between sample means was evaluated
using completely randomized one-way analysis of variance
(ANOVA). After a one-way ANOVA, post hoc comparisons
with the Scheffe method were used to determine the
individual levels of significant differences between control
(vehicle) and eszopiclone, control and zolpidem, and eszopi-
clone andzolpidem. Ap value of <0.05 was considered to be
statistically significant.
Results
In the present study, intraperitoneal injections of 1, 3, and
10 mg/kg of eszopiclone and 1, 3, and 10 mg/kg of
zolpidem, as well as control injections of vehicle were
performed in order to determine the effects of eszopiclone
and zolpidem on sleep and waking states in the aged guinea
pig. Control injection of vehicle was ineffective in modifying
the states of sleep or wakefulness. No statistically significant
changes in the time spent in sleep or wakefulness were
observed during the third and fourth hours following the
administration of either eszopiclone or zolpidem compared
with vehicle control sessions. Thus, the effects of eszopiclone
andzolpidemwerelimitedtochangesthatoccurredduringthe
first2hfollowingtheiradministration.Thefollowingsections
describeandcompare,quantitatively,theeffectsofeszopiclone
and zolpidem on the states of wakefulness, NREM, and REM
sleep, as well as EEG power, during the first 2 h following the
administration of these drugs.
Changes in the percentage of time spent in sleep
and waking states following the administration
of eszopiclone and zolpidem
Figure 1 presents an overview of the effects of the
administration of eszopiclone and zolpidem on the percent-
age of time spent in sleep and waking states in the aged
guinea pig. The following data are the results of an
ANOVA analysis that documents the significant effect on
the percentage of time spent in NREM sleep and waking
states that occurred a conjunction with the administration
of eszopiclone and zolpidem (NREM sleep: df=6,71, F=
18.35, p<0.001; wakefulness: df=6,71, F=16.33, p<0.001).
Compared to vehicle injections, the administration of
eszopiclone at 1, 3, and 10 mg/kg resulted in significant
increases in the time spent in NREM sleep by 34.0%, 65.7%,
and 85.1% (vehicle 26.8±1.6%, n=12; 1 mg/kg eszopiclone
35.9±1.7%, n=12, p=0.037; 3 mg/kg eszopiclone 44.4±
1.7%, n=12, p<0.001; 10 mg/kg eszopiclone 49.6±2.1%,
n=8, p<0.001, post hoc Scheffe method) and decreases in
wakefulness by 12.0%, 23.7%, and 30.6% (vehicle 72.2±
1.8%, n=12; 1 mg/kg eszopiclone 63.5±1.7%, n=12, p=
0.064; 3 mg/kg eszopiclone: 55.1±1.7%, n=12, p<0.001;
10 mg/kg eszopiclone 50.1±2.2%, n=8, p<0.001, post hoc
Scheffe method), respectively.
Following the injection of zolpidem at 1 mg/kg, there
were no significant changes in the percentage of time spent
in sleep and waking states. However, the administration of
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percentage of time spent in NREM sleep by 35.4% and
37.7% (3 mg/kg zoipidem 36.4±1.8%, n=12, p=0.022;
10 mg/kg zoipidem 36.9±1.8%, n=10, p=0.021, post hoc
Scheffe method) and decreased the time spent in wakeful-
ness by 12.5% and 13.4% (3 mg/kg zoipidem 63.2±1.8%,
n=12, p=0.049; 10 mg/kg zoipidem: 62.5±1.9%, n=10,
p=0.039, post hoc Scheffe method), respectively.
A significant difference in the percentage of NREM
sleep and wakefulness was observed on the basis of post
hoc analyses following the administration of eszopiclone
compared to zolpidem. The administration of eszolpiclone
at 3 mg/kg (but not at 1 mg/kg) resulted in an increase in
the percentage of time spent in NREM sleep and a decrease
in wakefulness that was significantly greater than the time
spent in these states after the administration of 1 mg/kg of
zolpidem (NREM sleep 3 mg/kg eszopiclone vs. 1 mg/kg
zolpidem, p<0.001; wakefulness 3 mg/kg eszopiclone vs.
1 mg/kg zolpidem, p<0.001, post hoc Scheffe method).
The administration of eszolpiclone at 10 mg/kg also resulted
in a significant increase in NREM sleep and a decrease in
wakefulness compared to the time spent in these states after
the administration of 1, 3, or 10 mg/kg of zolpidem (NREM
sleep 10 mg/kg eszopiclone vs. 1 mg/kg zolpidem, p<0.001,
10 mg/kg eszopiclone vs. 3 mg/kg zolpidem, p=0.001;
10 mg/kg eszopiclone vs. 10 mg/kg zolpidem, p=0.004;
wakefulness 10 mg/kg eszopiclone vs. 1 mg/kg zolpidem,
p<0.001; 10 mg/kg eszopiclone vs. 3 mg/kg zolpidem, p=
0.002; 10 mg/kg eszopiclone vs. 10 mg/kg zolpidem, p=
0.008, post hoc Scheffe method).
Following the injection of eszopiclone or zolpidem at 1,
3, or 10 mg/kg, there was no significant change in the time
spent in REM sleep (df=6,71, F=0.86, p=0.527, ANOVA),
although there was a tendency toward a decrease in the
REM sleep following the injection of eszopiclone or
zolpidem at the higher doses of 3 or 10 mg/kg.
Changes in the latency to NREM and REM sleep following
the administration of eszopiclone and zolpidem
Figure 2 presents the effects of eszopiclone and zolpidem
on the mean latency to the onset of the first episode of
NREM and REM sleep following the administration of
these drugs. Significant drug effects occurred as revealed
by ANOVA analysis with respect to the latency to both
NREM sleep and REM sleep (NREM sleep: df=6,71, F=
13.88, p<0.001; REM sleep: df=6,27, F=4.82, p=0.002).
Following the injection of eszopiclone at 1, 3, and
10 mg/kg, the mean latency to NREM sleep was signifi-
cantly shorter compared with vehicle controls, respectively
(1 mg/kg eszopiclone vs. vehicle, p<0.001; 3 mg/kg
eszopiclone vs. vehicle, p<0.001; 10 mg/kg eszopiclone vs.
vehicle, p<0.001, post hoc Scheffe method). Eszopiclone at
3 and 10 mg/kg also significantly increased the mean latency
to REM sleep (3 mg/kg eszopiclone vs. vehicle, p=0.032;
10 mg/kg eszopiclone vs. vehicle, p=0.034, post hoc Scheffe
method).
There were no significant changes in the mean latency to
NREM sleep following the injection of zolpidem at 1 and
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Fig. 1 Effects of eszopiclone and zolpidem on the mean percentage of
time spent in wakefulness, NREM sleep, and REM sleep during the
first 2-h period following the administration of these drugs at the
doses of 1, 3, and 10 mg/kg in the aged guinea pig (n=5). Each bar
represents the mean value; error bars indicate the SEM of each
population. *p<0.05, **p<0.01, ***p<0.001 vs. vehicle control
group; +++p<0.001 vs. 1 mg/kg zolpidem group; ##p<0.01 vs.
3 mg/kg zolpidem group; ^^p<0.01 vs. 10 mg/kg zolpidem group by
post hoc Scheffe method
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in the latency to NREM sleep at 3 mg/kg. However,
zolpidem at 10 mg/kg resulted in a significant decrease in
the latency to NREM sleep (10 mg/kg zolpidem vs. vehicle,
p=0.001, post hoc Scheffe method). There was no effect on
the latency to REM sleep with any dose of zolpidem.
Following the injection of eszopiclone at 1, 3, and
10 mg/kg, the mean latency to NREM sleep was sig-
nificantly shorter than that following zolpidem administra-
tion at doses of 1 mg/kg, respectively (1 mg/kg eszopiclone
vs. 1 mg/kg zolpidem, p=0.005; 3 mg/kg eszopiclone vs.
1 mg/kg zolpidem, p<0.001; 10 mg/kg eszopiclone vs.
1 mg/kg zolpidem, p<0.001, post hoc Scheffe method).
Changes in the duration and frequency of episodes of sleep
and wakefulness following the administration
of eszopiclone and zolpidem
The effects on the duration of episodes of sleep and waking
states were examined after the injection of eszopiclone and
zolpidem (Fig. 3). ANOVA revealed significant drug effects
vis-à-vis the duration of episodes of NREM sleep (df=6,71
F=6.78, p<0.001). Following the injection of eszopiclone
at 3 and 10 mg/kg, the mean duration of the episodes of
NREM sleep was significantly longer than the episodes of
NREM that occurred with vehicle (3 mg/kg eszopiclone vs.
vehicle p=0.011; 10 mg/kg eszopiclone vs. vehicle p=
0.002, post hoc Scheffe method). Eszopiclone at 3 and
10 mg/kg also resulted in a significant decrease in the mean
duration of episodes of wakefulness (3 mg/kg eszopiclone
vs. vehicle p=0.040; 10 mg/kg eszopiclone vs. vehicle p=
0.034, post hoc Scheffe method). No significant effects on
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injection of eszopiclone at 1 mg/kg.
Following the injection of zolpidem at all doses, the
mean duration of episodes of NREM sleep and wakefulness
was not significantly different from that following the
injection of vehicle. However, there was a tendency for an
increase in the duration of episodes of NREM sleep and a
decrease in the duration of episodes of wakefulness
following the administration of zolpidem, but only at 3 or
10 mg/kg.
Post hoc analyses revealed a significant increase in the
mean duration of episodes of NREM sleep following
the injection of eszopiclone at 10 mg/kg compared to the
duration of NREM sleep episodes following the injection of
1 or 3 mg/kg of zolpidem (10 mg/kg eszopiclone vs. 1 mg/kg
zolpidem, p=0.012; 10 mg/kg eszopiclone vs. 3 mg/kg
zolpidem, p=0.023, post hoc Scheffe method).
Following the administration of eszopiclone and zolpidem
at all doses, the frequency of episodes of NREM sleep, REM
sleep, and wakefulness was not significantly different from
that following the injection of vehicle, although there was a
tendency for a reduction in the frequency of episodes of
REM sleep following the administration of zolpidem at 3
or 10 mg/kg.
Changes in spectral EEG power following
the administration of eszopiclone and zolpidem
The effects of eszopiclone and zolpidem on EEG power
during NREM sleep are shown in Fig. 4, which consists of
plots of relative EEG power density during NREM sleep
following the injection of eszopiclone, zolpidem, and
vehicle. ANOVA revealed significant drug effects on the
relative EEG power in the delta and theta bands during
NREM sleep which occurred following the injection of
eszopiclone and zolpidem (the delta band: df=6,71 F=6.73,
p<0.001; the theta band: df=6,71 F=7.80, p<0.001).
Eszopiclone, at a dose of 3 or 10 mg/kg, significantly
increased EEG power in the delta band (vehicle 38.6±0.6 %,
n=12; 3 mg/kg eszopiclone 41.8±0.4 %, n=12, p=0.026;
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Scheffe method) and reduced EEG power in the theta
band (vehicle: 23.8±0.3 %, n=12; 3 mg/kg eszopiclone
22.2±0.3%, n=12,p=0.085; 10 mg/ kg eszopiclone 21.8±
0.3%, n=8, p=0.037, post hoc Scheffe method). EEG
power in the sigma and beta bands were not significantly
altered following the administration of eszopiclone at 1, 3,
or 10 mg/kg. However, there were no significant changes
in EEG power in any of the frequency bands analyzed
during NREM sleep following zolpidem administration at
any dose.
Comparisons between eszopiclone and zolpidem injec-
tions with post hoc analyses revealed that eszopiclone
administration at 3 or 10 mg/kg significantly increased the
relative power of the EEG in the delta band compared to
that after zolpidem administration at 1 mg/kg (3 mg/kg
eszopiclone vs. 1 mg/kg zolpidem, p=0.003; 10 mg/kg
eszopiclone vs. 1 mg/kg zolpidem, p=0.004, post hoc
Scheffemethod).Eszopicloneadministrationat3or10mg/kg
alsosignificantlyreducedthe relativepower ofthe EEGinthe
theta band compared to that after zolpidem administration
at both doses (3 mg/kg eszopiclone vs. 1 mg/kg zolpidem,
p=0.004; 10 mg/kg eszopiclone vs. 1 mg/kg zolpidem,
p=0.002; 3 mg/kg eszopiclone vs. 3 mg/kg zolpidem, p=
0.049; 10 mg/kg eszopiclone vs. 3 mg/kg zolpidem, p=
0.021, post hoc Scheffe method).
EEG power during REM sleep was examined following
the administration of any doses of eszopiclone and
zolpidem. Neither eszopiclone nor zolpidem resulted in
any significant change in EEG power in any of the
frequency bands analyzed during REM sleep.
Discussion
In the following sections, we discuss the effects of
eszopiclone and zolpidem on the states of sleep and
wakefulness in the aged guinea pig. These data are also
compared with data obtained from our previous study in the
adult guinea pig (Xi and Chase 2008) and reports of the
effectiveness of these hypnotics in adult animals of other
species. The differential binding properties of eszopiclone
and zolpidem vis-à-vis specific subunits of the GABAA
receptors and the effect of age on the activity of GABAA
receptors are suggested to be responsible partially for the
changes in the effects of these hypnotics in old age.
Hypnotic effects of eszopiclone in the aged guinea pig
In aged guinea pigs, the administration of eszopiclone
resulted in significant changes in NREM sleep at doses of
1, 3, and 10 mg/kg that consisted of an increase in the
amount of NREM sleep. This increase was accompanied by
a significant decrease in wakefulness. Eszopiclone also
significantly reduced the latency to NREM sleep and
increased the latency to REM sleep. Furthermore, there
was a significant increase in the duration of episodes of
NREM sleep and a decrease in the duration of episodes of
wakefulness following the administration of eszopiclone at
3 and 10 mg/kg. Finally, no significant effects on the time
spent in REM sleep were observed following the adminis-
tration of eszopiclone, although there was a tendency for
eszopiclone to reduce the amount of REM sleep.
Compared with data obtained from our previous study in
adult guinea pigs (Xi and Chase 2008), it is interesting to
note that the increase in NREM sleep and the reduction in
wakefulness following the administration of eszopiclone in
the aged guinea pig were smaller than were the changes that
occurred when equivalent doses were administrated in adult
animals (Table 1). In addition, eszopiclone produced a
significant increase in the duration of episodes of NREM
sleep at 1 and 3 mg/kg in the adult guinea pig, but there
was an increase in the duration of NREM sleep episodes
only at a dose of 3 mg/kg in the aged guinea pig. However,
eszopiclone (1 and 3 mg/kg) resulted in a significant, and
comparable, decrease in the mean latency to NREM sleep
in both aged and adult animals.
Our previous study in the adult guinea pig demonstrated
that there is a significant increase in EEG power in the delta
band (0.5–4.0 Hz) and a decrease in EEG power in the theta
band (4.0–9.0 Hz) during NREM sleep following the
administration of eszopiclone at either 1 or 3 mg/kg (Xi
and Chase 2008). In contrast, the present data revealed that
there were no significant changes in EEG power in any of
the frequency bands analyzed during NREM sleep follow-
ing eszopiclone administration at 1 mg/kg in aged animals.
However, eszopiclone at 3 mg/kg did produce a significant
increase in EEG power in the delta band during NREM
sleep in the aged animals. There were no significant
changes in either the time spent in REM sleep or EEG
power during REM sleep following the injection of
eszopiclone at either dose in aged guinea pigs, which is
similar to the results in the adult animal (Xi and Chase
2008).
The preceding data indicate that in aged guinea pigs, the
effects of eszopiclone on sleep and waking states (an
increase in NREM and a decrease in wakefulness) and in
the power spectra of the EEG during NREM sleep (an
increase in delta power) were significant but not quite as
strong as the effects produced in adult animals. Zopiclone
(presumably eszopiclone) exhibits considerable binding not
only to α1 subunits of the GABAA receptor, but also to
GABAA receptors containing α2, α3, and α5 subunits
(Damgen and Luddens 1999; Davies et al. 2000; Smith et
al. 2001). A recent study has demonstrated that there is a
significant decrease in the expression of α3a n dα5
Psychopharmacology (2009) 205:107–117 113subunits of GABAA receptors in aged rats compared with
young adult animals (Yu et al. 2006). Therefore, we suggest
that a decline in the expression of one or more of these
subunits of GABAA receptors in aged animals may provide
an explanation for the relatively “weaker” effects of
eszopiclone in aged guinea pigs compared to adult guinea
pigs.
While no reports have compared the effects of eszopi-
clone or zopiclone on sleep and waking states either in aged
guinea pigs or in aged animals of other species, the present
results are generally consistent with findings from separate
studies in animals and in humans. In adult rats, zopiclone,
administered intraperitoneally in doses from 2.5 to 10 mg/kg,
was found to increase NREM sleep, decrease wakefulness,
decrease the latency to NREM sleep, and increase the latency
to REM sleep (Stutzmann et al. 1992); a decrease in the total
time spent in REM sleep was also reported (Gutierrez et al.
1997). However, in another study, zopiclone also signifi-
cantly increased NREM sleep but had no effect on REM
sleep in the adult rat (Noguchi et al. 2004). Spectral analyses
in adult rabbits revealed that zopiclone, at a dose of 2 mg/kg,
significantly increased power in the delta frequency band
and decreased power in the theta frequency band (Noguchi
et al. 2002). In humans, zopiclone has been shown to have a
positive effect on sleep (e.g., a reduction in sleep latency and
an increase in total NREM sleep time) with few adverse
responses in healthy elderly subjects (Hemmeter et al. 2000).
Zopiclone also significantly shortened sleep latency and
increased total sleep time in elderly patients with insomnia
(Scharf et al. 2005). In young healthy subjects, Zopiclone
has been reported to produce a minor increase in EEG
delta power, a significant decrease in EEG theta power
and an increase in EEG sigma power (Kim et al. 1993).
However, other studies have reported that zopiclone
decreases the power density in other frequency ranges
<10 Hz and enhances the power density in the range of
12–15 Hz in adult healthy subjects (Trachsel et al. 1990;
Wright et al. 1986).
There was a positive relationship between the increase in
EEG power of the delta frequency band during NREM
sleep and the increase in the duration of NREM episodes or
the amount of NREM sleep following the administration of
eszopiclone. The magnitude of EEG slow wave activity in
the delta band is considered to be an index of sleep intensity
(Borbely and Achermann 2000; Tobler and Borbely 1986).
This is particularly interesting with respect to the use of
eszopiclone as a pharmacological tool to improve the quality
of sleep in old age, especially when one considers the fact
that there is a reduction in delta wave activity in aged
humans (Mann and Roschke 2004).
Hypnotic effects of zolpidem in the aged guinea pig
In the aged guinea pig, significant changes in sleep and
waking states occurred when zolpidem was administered
but only at a dose of 3 or 10 mg/kg. At these doses, it
Table 1 Hypnotic effects of eszopiclone and zolpidem in adult and aged guinea pigs
Eszopiclone Zolpidem
1mg/kg 3mg/kg 1mg/kg 3mg/kg
Adult
a Aged Adult
a Aged Adult
a Aged Adult
a Aged
Wakefulness 25%↓
*** n.c. 34%↓
*** 24%↓
*** n.c. n.c. 13%↓
* 13%↓
*
NREM Sleep 60%↑
*** 34%↑
* 81%↑
*** 66%↑
*** n.c. n.c. 32%↑
* 35%↑
*
NREM latency 68%↓
*** 70%↓
*** 85%↓
*** 82%↓
*** n.c. n.c. n.c. n.c.
REM Latency 82%↑
* n.c. 117%↑
** 70%↑
* n.c. n.c. n.c. n.c.
Wakefulness Duration n.c. n.c. 35%↓
* 36%↓
* n.c. n.c. n.c. n.c.
NREM Sleep Duration 35%↑
* n.c. 65%↑
*** 60%↑
* n.c. n.c. n.c. n.c.
REM Sleep Frequency n.c. n.c. 50%↓
* n.c. n.c. n.c. n.c. n.c.
Delta Power 10%↑
* n.c. 13%↑
** 8%↑
* n.c. n.c. n.c. n.c.
Theta Power 7%↓
** n.c 8%↓
** n.c. n.c. n.c. n.c n.c
An increase (↑) or decrease (↓) in the percentage of changes in sleep and waking states compared with control (vehicle) data are presented at 1 and
3 mg/kg for eszopiclone and zolpidem in adult and aged guinea pigs. Data regarding the percentage of time spent in REM sleep, the duration of
episodes of REM sleep, the frequency of episodes of NREM sleep and wakefulness, EEG power in sigma and beta bands following the
administration of eszopiclone or zolpidem at both doses, which were not significantly different from those of vehicle-injected controls, are not
included in this table. *P<0.05; **P<0.01; ***P<0.001. Post hoc comparisons with the Scheffe method were used to determine the levels of
significant differences between drugs and control (vehicle)
n.c. no significant change
aXi and Chase (2008)
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decreased the amount of wakefulness. There were no
significant effects on the time spent in REM sleep with
either dose of zolpidem.
It is interesting to note that the changes in the percentage
of time spent in NREM sleep following the administration
of zolpidem at 1 and 3 mg/kg in the aged guinea pig were
similar to those that occurred when the same doses were
administrated to adult guinea pigs (Xi and Chase 2008;
Table 1). In addition, there were no significant changes in
EEG power in any of the frequency bands analyzed during
NREM sleep following zolpidem administration in the aged
guinea pig, which mirrors our findings in the adult guinea
pig (Xi and Chase 2008). Therefore, the present data
indicate that there are no marked differences in the effects
of zolpidem on sleep and waking states (increase in NREM
and decrease in wakefulness) and in the power spectra of
the EEG during NREM sleep in aged guinea pigs compared
with adult guinea pigs.
Zolpidem is known to exert its hypnotic effects by acting
primarily on α1 subunits of GABAA receptors (Sanna et al.
2002). A number of anatomical studies have shown that
there is no prominent change in the expression of α1
subunits of the GABAA receptor in aged rats compared
with adult animals (Gutierrez et al. 1997; Mhatre and Ticku
1992; Yu et al. 2006). Therefore, this may explain the lack
of marked differences in the effects of zolpidem in aged and
adult guinea pigs. However, additional research is needed
to unravel bases of the differences in the effects produced
by eszopiclone and zolpidem vis-à-vis changes in the
subunits of GABAA receptors that are targeted by these
hypnotics in aged animals.
Our results with zolpidem in the aged guinea pig are
generally similar to data of previous studies in adult
animals of other species. For example, studies in adult
rats have shown that zolpidem, administered at doses of
3o r1 0m g / k g ,i n c r e a s e dN R E Ms l e e pa n dt h em e a n
duration of episodes of NREM sleep during the light
period and dark period, respectively (Chen et al. 2005;
Depoortere et al. 1991; Mailliet et al. 2001). Another study
in the adult rat reported that the latency to NREM was
reduced following the administration of zolpidem at 2.5, 5,
and 7.5 mg/kg, and the latency to REM sleep was only
increased at the two higher doses. In addition, the amount
of REM sleep decreased at the highest dose (Gottesmann
et al. 1998).
In normal elderly human subjects, zolpidem, in doses
between 5 and 20 mg, shortens the latency to NREM
sleep and increases the total time spent in NREM sleep
(Fairweather et al. 1992; Scharf et al. 1991). In elderly
patients with insomnia, zolpidem has been reported to
shorten sleep latency and increase total sleep time (Ancoli-
Israel et al. 1999; Walsh et al. 2008).
Differences between hypnotic effects of eszopiclone
and zolpidem in the aged guinea pig
While the administration of both eszopiclone and zolpidem
in aged guinea pigs produced hypnotic effects in the present
study, our quantitative analyses reveal significant differ-
ences in the effects of these two hypnotics. Firstly, the
increase in the percentage of time spent in NREM sleep and
the decrease in the time spent in wakefulness following the
administration of eszopiclone at 3 or 10 mg/kg were
significantly greater than the time spent in NREM sleep
and wakefulness after zolpidem administration (which was
ineffective at a dose of 1 mg/kg). Secondly, eszopiclone at
1 and 3 mg/kg induced a significant decrease in the mean
latency to NREM sleep that was significantly shorter than
that which followed the administration of zolpidem at
1 mg/kg. Thirdly, eszopiclone at 3 or 10 mg/kg resulted in a
significant increase in the mean duration of episodes of
NREM sleep, whereas zolpidem did not produce any
significant change in the mean duration of episodes of
NREM sleep at any doses. Finally, there was a significant
increase in EEG power in the delta band and a decrease in
EEG power in the theta band during NREM sleep following
the administration of eszopiclone at 3 or 10 mg/kg. In
contrast, there were no significant changes in EEG power in
any of the frequency bands analyzed during NREM sleep
following zolpidem administration at any dose. Therefore,
the present data suggest that eszopiclone has a greater
effect on NREM sleep and the generation of NREM delta
activity than does zolpidem in the aged guinea pig, which
is similar to the results obtained in the adult guinea pig
(Xi and Chase 2008).
In summary, the present results demonstrate that in the
aged guinea pig, eszopiclone, compared with zolpidem, has
a more rapid onset of hypnotic action and results in an
increased amount in NREM sleep. In addition, eszopiclone
produces an increase in EEG delta power, whereas
zolpidem has no effect on delta activity. Compared with
previous data obtained in the adult guinea pig, the effects of
eszopiclone on sleep and waking states and in the power
spectra of the EEG during NREM sleep in the aged guinea
pig were “weaker” than those in the adult guinea pig,
although the effects of zolpidem were similar in aged and
adult guinea pigs (Xi and Chase 2008). We, therefore,
suggest that in addition to the potential differences in
pharmacokinetics and pharmacodynamics of these two
drugs (Drover 2004), the relative binding properties of
eszopiclone and zolpidem, and the reduction in the
expression of specific subunits of GABAA receptors in
aged animals may account for the changes in the relative
degree of effectiveness of eszopiclone and zolpidem on the
states of sleep and wakefulness as well as the power spectra
of the EEG in the aged guinea pig.
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